Skip to content

5-MeO-DMT: all studies

Page 65 of 110: studies 641 to 650 of 1,096, newest first. Back to the 5-MeO-DMT overview

Research

The mitogenomic landscape of Banisteriopsis caapi (Malpighiaceae), the sacred liana used for ayahuasca preparation.

Genetics and molecular biology 2024 Edisson Chavarro-Mesa, João Victor Dos Anjos Almeida, Saura R Silva et al. 2 citations

The sacred ayahuasca brew, utilized by indigenous communities in the Amazon and syncretic religious groups in Brazil, primarily consists of a decoction of two plants: (i) the Amazonian liana known as Mariri or Jagube (Banisteriopsis caapi), and (ii) the shrub referred as Chacrona or Rainha (Psychotria viridis). While Chacrona leaves are rich in N,N-Dimethyltryptamine (DMT), a potent...

DOI: 10.1590/1678-4685-gmb-2023-0301 (opens in new tab) Full text (opens in new tab) Psychedelics Genetics Amazonian plants Ethnobotany +1

Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects

Neuroscience of Consciousness 2024 Charlotte Martial, Robin Carhart-Harris, Christopher Timmermann 9 citations

Abstract Mystical-like states of consciousness may arise through means such as psychedelic substances, but may also occur unexpectedly during near-death experiences (NDEs). So far, research studies comparing experiences induced by serotonergic psychedelics and NDEs, along with their enduring effects, have employed between-subject designs, limiting direct comparisons. We present results from an...

DOI: 10.1093/nc/niae033 (opens in new tab) Full text (opens in new tab) Consciousness studies phenomenology Altered states Awareness Impact +8

Ayahuasca for the treatment of alcohol use disorder.

International review of neurobiology 2024 Eduardo A V Marinho, Yasmim A. Serra, Alexandre J. Oliveira-Lima et al. 6 citations

For decades, psychedelics have been investigated for the treatment of psychiatric disorders. Specifically, evidence suggests that psychedelics may have therapeutic potential for the treatment of alcohol use disorder. Several studies with classic psychedelics, including LSD and psilocybin, show promising results, with psychedelics decreasing alcohol drinking and promoting abstinence in...

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans

Biomedicine & Pharmacotherapy December 31, 2023 David Fabregat-Safont, Alex Gomez-Gomez, Francisco Madrid-Gambin et al.

Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand their biological effects in humans, their mechanism of action, and their metabolism in humans is...

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie December 31, 2023 Francisco Madrid-Gambin, David Fabregat-Safont, Alex Gomez-Gomez et al. 12 citations

Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand their biological effects in humans, their mechanism of action, and their metabolism in humans is...

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part V. Ibogaine

December 26, 2023 Kirsten Cherian, Kenneth Shinozuka, Burton J. Tabaac et al. preprint

Background: Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric indications, including post-traumatic stress disorder (PTSD), depression, anxiety, and traumatic brain...

Trajectories of sentiment in 11,816 psychoactive narratives

Human Psychopharmacology: Clinical and Experimental December 20, 2023 Sam Friedman, Galen Ballentine 5 citations

Abstract Objective Can machine learning (ML) enable data‐driven discovery of how changes in sentiment correlate with different psychoactive experiences? We investigate by training models directly on text testimonials from a diverse 52‐drug pharmacopeia. Methods Using large language models (i.e. BERT) and 11,816 publicly‐available testimonials, we predicted 28‐dimensions of sentiment across each...

DOI: 10.1002/hup.2889 (opens in new tab) Narrative Surprise Parallels Cognitive psychology

Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.

Drug Discovery Today December 1, 2023 Taeho Greg Rhee, Pasha A. Davoudian, Gerard Sanacora et al. 20 citations

Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic agents for psychiatric disorders has recently re-emerged. Here, we review progress in the development of psychedelic compounds that have potential therapeutic effects as well as the safety concerns. We include psilocybin, N,N-dimethyltryptamine (DMT),...

Toad in the road: Biocultural history and conservation challenges of the Sonoran Desert Toad

Journal of Psychedelic Studies November 30, 2023 R Villa 5 citations

Abstract The Sonoran Desert Toad ( Incilius alvarius ) is the only vertebrate known to produce the powerful psychedelic, 5-MeO-DMT, which is easily-accessible form the animal's exterior glands. This paper seeks to present the biocultural (ecological and cultural) history, and conservation concerns of I. alvarius . Discovery of 5-MeO-DMT in I. alvarius was first reported in 1965 and 1967...

DOI: 10.1556/2054.2023.00269 (opens in new tab) Full text (opens in new tab) Indigenous Outreach Desert philosophy Environmental ethics +5

Drug–drug interactions involving classic psychedelics: A systematic review

Journal of Psychopharmacology November 20, 2023 Andreas Halman, Geraldine Kong, Jerome Sarris et al. 42 citations

Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychoactive substances that have been studied for their physiological and psychological effects. However, our understanding of the potential interactions and outcomes when using these substances in combination with...